Anthony D. Elias, MD

Currently, there is a maturing, randomized phase II study of exemestane, plus or minus, enzalutamide in AR-positive breast cancer, says Elias.

Data have been collected in triple-negative breast cancer with enzalutamide, and Elias says it is fairly compelling. He adds that there is potential action on more aggressive, triple-negative breast cancer, and Elias believes combinations will be particularly significant. Examples include combinations with anti-estrogen therapy and everolimus, anti-estrogen therapy and palbociclib, CDK4/6 inhibitors with enzalutamide, etc.

Anthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado School of Medicine, discusses the future of androgen receptors in breast cancer.

Videos

Anthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado Denver, discusses the future of androgen receptors in breast cancer. 


Anthony D. Elias, MD | Authors

Articles

Dr. Elias Discusses the Future of Androgen Receptors in Breast Cancer